Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and ...

On March 24, the Centers for Disease Control and Prevention (CDC) issued a Health Alert Network Health Advisory to clinicians and public health officials regarding the increase in global and U.S.

PD as best response Worse PFS CR/PR as best response Improved PFS ...

Rates of surgical site infections and length of stay following major gynecologic oncology surgery for patients on federally funded insurance: A 6-month retrospective cohort.

Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.

Phase 1 trial of GD2-SADA: 177 Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and ...

Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status.

Evaluating the diagnostic performance of 18 F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.

Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG).

Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer.

Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF V600-positive melanoma: Interim analysis of the ...

Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAF V600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.